ARDX
Price
$4.89
Change
-$0.00 (-0.00%)
Updated
Nov 11 closing price
112 days until earnings call
CARM
Price
$1.00
Change
-$0.00 (-0.00%)
Updated
Nov 11 closing price
Ad is loading...

ARDX vs CARM

Header iconARDX vs CARM Comparison
Open Charts ARDX vs CARMBanner chart's image
Ardelyx
Price$4.89
Change-$0.00 (-0.00%)
Volume$10.69M
CapitalizationN/A
Carisma Therapeutics
Price$1.00
Change-$0.00 (-0.00%)
Volume$253.13K
CapitalizationN/A
ARDX vs CARM Comparison Chart
Loading...
ARDX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
CARM
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
ARDX vs. CARM commentary
Nov 13, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARDX is a Hold and CARM is a Buy.

COMPARISON
Comparison
Nov 13, 2024
Stock price -- (ARDX: $4.89 vs. CARM: $1.00)
Brand notoriety: ARDX and CARM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARDX: 283% vs. CARM: 151%
Market capitalization -- ARDX: $1.16B vs. CARM: $41.34M
ARDX [@Biotechnology] is valued at $1.16B. CARM’s [@Biotechnology] market capitalization is $41.34M. The market cap for tickers in the [@Biotechnology] industry ranges from $492.19B to $0. The average market capitalization across the [@Biotechnology] industry is $2.81B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARDX’s FA Score shows that 0 FA rating(s) are green whileCARM’s FA Score has 0 green FA rating(s).

  • ARDX’s FA Score: 0 green, 5 red.
  • CARM’s FA Score: 0 green, 5 red.
According to our system of comparison, ARDX is a better buy in the long-term than CARM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARDX’s TA Score shows that 2 TA indicator(s) are bullish while CARM’s TA Score has 6 bullish TA indicator(s).

  • ARDX’s TA Score: 2 bullish, 7 bearish.
  • CARM’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, CARM is a better buy in the short-term than ARDX.

Price Growth

ARDX (@Biotechnology) experienced а -16.89% price change this week, while CARM (@Biotechnology) price change was -4.76% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.24%. For the same industry, the average monthly price growth was +11.71%, and the average quarterly price growth was +7.66%.

Reported Earning Dates

ARDX is expected to report earnings on Mar 05, 2025.

CARM is expected to report earnings on May 15, 2023.

Industries' Descriptions

@Biotechnology (+1.24% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARDX($1.16B) has a higher market cap than CARM($41.3M). ARDX YTD gains are higher at: -25.968 vs. CARM (-66.041). ARDX has higher annual earnings (EBITDA): -53.06M vs. CARM (-72.61M). ARDX has more cash in the bank: 190M vs. CARM (40.4M). CARM has less debt than ARDX: CARM (8.17M) vs ARDX (104M). ARDX has higher revenues than CARM: ARDX (252M) vs CARM (20.7M).
ARDXCARMARDX / CARM
Capitalization1.16B41.3M2,806%
EBITDA-53.06M-72.61M73%
Gain YTD-25.968-66.04139%
P/E RatioN/AN/A-
Revenue252M20.7M1,217%
Total Cash190M40.4M470%
Total Debt104M8.17M1,273%
FUNDAMENTALS RATINGS
ARDX vs CARM: Fundamental Ratings
ARDX
CARM
OUTLOOK RATING
1..100
544
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
94
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9699
PRICE GROWTH RATING
1..100
6463
P/E GROWTH RATING
1..100
65100
SEASONALITY SCORE
1..100
95n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CARM's Valuation (94) in the null industry is in the same range as ARDX (97) in the Biotechnology industry. This means that CARM’s stock grew similarly to ARDX’s over the last 12 months.

CARM's Profit vs Risk Rating (100) in the null industry is in the same range as ARDX (100) in the Biotechnology industry. This means that CARM’s stock grew similarly to ARDX’s over the last 12 months.

ARDX's SMR Rating (96) in the Biotechnology industry is in the same range as CARM (99) in the null industry. This means that ARDX’s stock grew similarly to CARM’s over the last 12 months.

CARM's Price Growth Rating (63) in the null industry is in the same range as ARDX (64) in the Biotechnology industry. This means that CARM’s stock grew similarly to ARDX’s over the last 12 months.

ARDX's P/E Growth Rating (65) in the Biotechnology industry is somewhat better than the same rating for CARM (100) in the null industry. This means that ARDX’s stock grew somewhat faster than CARM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARDXCARM
RSI
ODDS (%)
Bullish Trend 1 day ago
88%
Bearish Trend 1 day ago
88%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
83%
Momentum
ODDS (%)
Bearish Trend 1 day ago
72%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
79%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
79%
Bearish Trend 1 day ago
88%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
82%
Bullish Trend 1 day ago
82%
Advances
ODDS (%)
Bullish Trend 15 days ago
87%
Bullish Trend 7 days ago
83%
Declines
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
80%
Bullish Trend 1 day ago
81%
View a ticker or compare two or three
Ad is loading...
ARDX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
CARM
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MLRTX11.600.05
+0.43%
NYLI Winslow Large Cap Growth Class R2
PXEAX24.77-0.21
-0.84%
Impax Global Environmental Markets A
APDNX16.02-0.16
-0.99%
Artisan Select Equity Advisor
WAIGX24.96-0.29
-1.15%
Wasatch International Growth Investor
BRECX27.34-0.56
-2.01%
BlackRock International Dividend Inv C

ARDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARDX has been loosely correlated with VCYT. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if ARDX jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARDX
1D Price
Change %
ARDX100%
-6.23%
VCYT - ARDX
45%
Loosely correlated
-1.65%
VTGN - ARDX
42%
Loosely correlated
-2.98%
PTGX - ARDX
42%
Loosely correlated
-7.12%
HRTX - ARDX
41%
Loosely correlated
-30.43%
BCRX - ARDX
41%
Loosely correlated
-4.52%
More

CARM and

Correlation & Price change

A.I.dvisor indicates that over the last year, CARM has been loosely correlated with PRME. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if CARM jumps, then PRME could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CARM
1D Price
Change %
CARM100%
-0.16%
PRME - CARM
40%
Loosely correlated
-1.59%
ARDX - CARM
37%
Loosely correlated
-6.23%
BEAM - CARM
36%
Loosely correlated
-7.94%
NTLA - CARM
35%
Loosely correlated
-4.86%
ABCL - CARM
35%
Loosely correlated
-6.35%
More